Last updated: 11/07/2018 15:10:44
European Pentasaccharide Hip Elective Surgery Study (EPHESUS): A multicenter, randomized, double-blind comparison of once daily subcutaneous Org31540/SR90107A with enoxaparin for the prevention of deep vein thrombosis or symptomatic pulmonary embolism in patients undergoing elective hip replacem ...
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: European Pentasaccharide Hip Elective Surgery Study (EPHESUS): A multicenter, randomized, double-blind comparison of once daily subcutaneous Org31540/SR90107A with enoxaparin for the prevention of deep vein thrombosis or symptomatic pulmonary embolism in patients undergoing elective hip replacem ...
Trial description: European Pentasaccharide Hip Elective Surgery Study (EPHESUS): A multicenter, randomized, double-blind comparison of once daily subcutaneous Org31540/SR90107A with enoxaparin for the prevention of deep vein thrombosis or symptomatic pulmonary embolism in patients undergoing elective hip replacem ...
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Abstract: Consistency of fondaparinux superiority over enoxaparin in prevention of venous thromboembolism cvte) in orthopaedic surgery according to different composite efficacy endpoints. K.A. Bauer, BJ, Eriksson, M.R. Lassen, and A. G.G. Turpie 7th Congress of the European Haematology Association 6/6/2002 Florence, Italy
Abstract: Fondaparinux is superior to enoxaparin for venous thromboembolism prevention in major orthopedic surgery irrespective of patient characteristics. A. G. Turpie, ' K. A. Bauer B. . Eriksson M. R. Lassen D. A. Smith. Annual Meeting of the American Geriatrics Society 5/14/2003 Orlando, FL, USA
Abstract: Influence of the duration of fondaparinux prophylaxis in preventing venous thromboembolism (vte) following major orthopedic surgery. Eriksson B., Bauert K. A. Lassen M. R. Turpie A. G. G. 19th Congress of the International Society on Thrombosis and Haemostasis and 49th Annual Scientific and Standardisation Committee Meeting 7/12/2003 Birmingham; UK
Abstract: Influence of the duration of fondaparinux prophylaxis in preventing venous thromboembolism following hip fracture surgery. B. Eriksson, ' K. A. Bauer M. R. Lassen A. G. Turpie D. A. Smithe. Annual Meeting of the American Geriatrics Society 5/14/2003 Orlando, FL, USA
Abstract: No episode of thrombocytopenia after four-week administration of fondaparinux, a new synthetic and selective inhibitor of factor xa, in the penthifra-plus study. Bauer, K. A. , Lassen, M. R. , Turpie, A. G. G. , and Eriksson, B. 19th Congress of the International Society on Thrombosis and Haemostasis and 49th Annual Scientific and Standardisation Committee Meeting 7/12/2003 Birmingham; UK
Abstract: Pentasaccharide (fondaparinux, arixtra@) versus enoxaparin for the prevention of venous thromboembolism (vte) in major orthopedic surgery: subgroup analyses on efficacy. MichaeIR. Lassen, Bengt1 Eriksson Kenneth A. Bauer Alexander G. G. Turpie. American Society of Hematology 43rd Annual Meeting 12/7/2001 Orlando, FL, USA
Abstract: Superior efficacy of fondaparinux versus enoxaparin for the prevention of venous thromboembolism in major orthopaedic surgery is maintained whatever patients, anesthesia and procedures characteristics. Eriksson, B I, Bauer, K A, Lassen, M R, Turpie, A G G, Bauersachs, R M, and Fondaparinux Orthopedic Prophylaxis Studies Investigators 7th Congress of the European Association of Hospital Pharmacists 3/20/2002 Vienna, Austria
Lassen MR. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 2002; 359: 1715-20.
Medical condition
Thrombosis, Venous
Product
Not applicable
Collaborators
Not applicable
Study date(s)
N/A to Invalid Date
Type
Not applicable
Phase
3
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
Not applicable
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website